SOURCE: BioMedReports

BioMedReports

April 09, 2012 10:45 ET

Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences

LOS ANGELES, CA--(Marketwire - Apr 9, 2012) - Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that it had completed an impressive, $40 million private placement financing. The development was noted as a particularly bullish sign for emerging biotechs everywhere.

In an exclusive interview, Timothy Mayleben, who has served as Aastrom's President and CEO since late 2009, explains how the financing came to be and why investors sought out his firm to place the big bet on their future.

Aastrom Biosciences is a regenerative medicine company engaged in the development of autologous cell products for treatment of severe, chronic cardiovascular diseases. Their proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. The cellular therapy resulting from this process contains expanded populations of mixed stem and progenitor cells to support the regeneration of cardiovascular tissue. The company's cell manufacturing process works exclusively with adult stem cells derived from and administered to the same patient. This approach reduces the risk of rejection and increases the likelihood of integration with the surrounding tissues, eliminating the need for immunosuppressive drugs.

Mayleben's exclusive interview with BioMedReports is now available at:

http://www.biomedreports.com/2012040992513/qaa-timothy-mayleben-ceo-of-aastrom-biosciences.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:

http://biomedreports.com/fdacal.html

News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556